Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to 4.0%.

  • Ascendis Pharma A's EBIT Margin rose 37800.0% to 4.0% in Q4 2025 from the same period last year, while for Dec 2025 it was 17.64%, marking a year-over-year increase of 595300.0%. This contributed to the annual value of 18.92% for FY2025, which is 577400.0% up from last year.
  • Per Ascendis Pharma A's latest filing, its EBIT Margin stood at 4.0% for Q4 2025, which was up 37800.0% from 5.15% recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's EBIT Margin peaked at 5.15% during Q3 2025, and registered a low of 16709.12% during Q1 2021.
  • Over the past 5 years, Ascendis Pharma A's median EBIT Margin value was 288.49% (recorded in 2023), while the average stood at 2227.94%.
  • In the last 5 years, Ascendis Pharma A's EBIT Margin plummeted by -134190000bps in 2021 and then surged by 148340600bps in 2022.
  • Over the past 5 years, Ascendis Pharma A's EBIT Margin (Quarter) stood at 130.71% in 2021, then plummeted by -393bps to 643.75% in 2022, then skyrocketed by 98bps to 12.09% in 2023, then soared by 102bps to 0.22% in 2024, then soared by 1716bps to 4.0% in 2025.
  • Its EBIT Margin stands at 4.0% for Q4 2025, versus 5.15% for Q3 2025 and 33.5% for Q2 2025.